OCU410 controlled lesion growth 46% better than placebo in dAMD-related GA.

Please provide your email address to receive an email when new articles are posted on . A 36-year-old Caucasian male presented with a chief complaint of mild blur in the left eye at distance and near ...

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Geographic atrophy (GA) is a late stage of age-related macular degeneration (AMD) associated with severe and irreversible, but gradual visual impairment. In its early stages, GA typically affects the ...

This is an image of a macular lesion in the eye of a baby with presumed Zika-induced microcephaly. Researchers from Brazil and Stanford University are reporting more eye abnormalities such as this in ...

Ocugen (OCGN) traded higher in the premarket on Thursday after the company said that OCU410, its gene therapy for an eye ...